Macrophage migration inhibitory factor (MIF) has been identified as a major gene product upregulated in breast cancer cells-tissues upon the accumulation of macrophages. However, regulatory role of MIF in tumor microenvironment is not well understood. Previously, we have developed small interfering RNA (siRNA)-loaded nanoparticle system to effectively reduce MIF expression in both breast cancer cells and macrophages. Using this nanoparticle system, in this study we demonstrated that the siRNA-induced MIF reduction in murine mammary cancer line 4T1 and human breast cancer line MDA-MB-231 resulted in significant reduction of cell proliferation and increase of apoptosis; the siRNA-induced MIF reduction in tumor-associated macrophages resulted in a significant reduction of surface expression of CD74 and CD206 and a significant increase of surface expression of major histocompatibility complex II, as well as intracellular expression of tumor necrosis factor-α and interleukin-2. A direct injection of the MIF-siRNA-loaded nanoparticles into 4T1 tumor in mice resulted in effective reduction of intratumoral MIF. This led to a reduction of tumor growth and metastasis. This also resulted in a reduction of circulating myeloid-derived suppressive cells both in number and in suppressive function. CD4 T-cell infiltration to tumor was increased. More importantly, this not only slowed the growth of treated 4T1 tumor, but also delayed the growth and metastasis of a contralateral untreated 4T1-luc tumor, suggesting the development of systemic antitumor responses. This study demonstrates for the first time that the siRNA-mediated intratumoral MIF reduction can induce antitumoral immune response via reducing systemic immune suppression.
INTRODUCTION
Metastasis is the main cause of morbidity and mortality in breast cancer patients. 1 Currently, a fundamental concept in metastatic research is that stromal cells mediate epigenetic mechanisms for cancer cells to gain metastatic traits to survive, self-renew, disseminate and metastasize. 2 Of all the stromal cells, a special focus has been given to tumor-associated macrophages (TAMs), as their accumulation in microenvironments of breast tumor has been found to positively correlate to metastasis formation. [3] [4] [5] [6] Critical event in tumor microenvironment that regulates and/or is regulated by TAM-tumor interaction is increasingly being viewed as potential therapeutic targets for cancers.
In breast tumor microenvironment where TAM accumulates, macrophage migration inhibitory factor (MIF) has been identified as a major gene product upregulated upon the infiltration and accumulation of TAMs. 7, 8 MIF has been found to associate with most of the cancers in all stages. 9 MIF is considered to have a role in cancer cell proliferation and differentiation because of its interaction with tumor-suppressor gene p53 thereby leading to uncontrolled cell growth. 10 Apart from the function of controlling cancer cell proliferation, MIF is considered a pluripotent cytokine that regulates inflammation and immune responses. For example, after MIF was first discovered in 1966 and thought to inhibit the migration of macrophages, 11 studies have shown that MIF correlates to macrophage in its functions such as phagocytosis, adherence, spreading and metabolism. 7 These findings strongly suggested the regulatory role of MIF in tumor microenvironment.
For past decades, MIF-targeted monoclonal antibodies and antagonist have been developed to neutralize extracellular MIF. 12 However, MIF functions differently in intracellular and extracellular spaces, both of which correlate to cancer development and metastasis. 13, 14 Considering of these, small interfering RNA (siRNA) technology demonstrates to be an ideal tool to silence MIF gene at mRNA level so that both intracellular and extracellular protein expression can be reduced effectively. 15 In this study, we used siRNA-loaded nanoparticle to effectively reduce extracellular and intracellular MIF both in vitro and in vivo. Our results have shown for the first time that the siRNA-induced MIF reduction in tumor microenvironment could not only inhibit mammary tumor growth and metastasis but also provoke systemic antitumor immune responses. This revealed the clinical significance of MIF as novel target in tumor microenvironment to develop innovative immunotherapeutic strategy for breast cancers. USA) and used as a scrambled siRNA (mismatched siRNA). The RNase-free water, RPMI-160 and Dulbecco's modified Eagle's medium (DMEM) cell culture media, fetal bovine serum, penicillin-streptomycin, cell-tissue fixative buffer, mounting medium, ProLong antifade kit, Hoechst blue 33342, Pacific blue-conjugated and fluorescein isothiocyanate (FITC)conjugated CD11b antibody, pac blue-and phycoerythrin (PE)-conjugated GR1 antibody, ACK red blood cell lysis buffer, rabbit anti-mouse MIF antibody, AF647-conjugated anti-rabbit antibody, granulocytemacrophage colony-stimulating factor, tissue lysis buffer, Lipofectamine 2000 were purchased from Invitrogen. PE-conjugated ki67, CD206, CD68, CD80, CD11b, dectin-1, CD25 and major histocompatibility complex (MHC) II were purchased from BD Biosciences (San Diego, CA, USA). The 4T1, 4T1-Luciferase (4T1-luc), 4T1-GFP, MDA-MB-231 and B16 cell lines were gift from Professor BC Wang's lab at Case Western Reserve University. The intracellular cytokine staining kit including staining buffer, cytofixcytoperm buffer and perm-wash buffer was purchased from BD Pharmingen (San Diego, CA, USA) and Mer&Ciel (www.meretciel.com). The Annexin V and 7-aminoactinomycin D (7AAD) apoptosis detection kit were purchased from BD Biosciences. The FITC-conjugated rabbit antimouse interleukin (IL)-1β, IL-10 and transforming growth factor (TGF)-β antibodies were purchased from R&D Systems (Minneapolis, MN, USA). Enzyme-linked immunosorbent assay (ELISA) kits for murine and human MIF were purchased from Mer&Ciel (www.meretciel.com). Reagents for tumor digest including collagenase type I, collagenase type IV, hyaluronidase, DNase I and soybean trypsin inhibitor were also from Sigma. The D-luciferin, acetic acid and 37% formalin was purchased from Fisher Scientific (Pittsburgh, PA, USA). India ink solution was purchased from Higgins (Bellwood, PA, USA). The 7-to 8-week-old female Balb/c mice were purchased from Charles River (Wilmington, MA, USA).
Preparation of nanoparticles
The scrambled siRNA and MIF-siRNA-loaded nanoparticles were prepared according to our previous publication. 16 Briefly, carrier agent and siRNA were dissolved in RNase-free water at 2.5 mg ml -1 and 0.1 μg μl -1 , respectively. Fifty microliters (5.0 μg) of MIF siRNA was mixed with 184 μl of carrier, followed by 20-to 30-min incubation, and then they were added to 1 × 10 6 cells in DMEM media. After 6 h, cells were washed with phosphate-buffered saline (PBS) and cultured in completed DMEM medium with 5% fetal bovine serum. For intratumoral administration, carrier agents and siRNA were dissolved in RNase-free water at 10 mg ml -1 and 0.4 μg μl -1 , respectively. Forty microliters (16 μg) of MIF siRNA was mixed with 147 μl of transfecting agent, followed by 20-to 30-min incubation, and then used for direct intratumoral injection for each mouse.
Cell culture
Cancer cells were cultured in DMEM medium supplemented with 10% (v/v) fetal bovine serum and penicillin-streptomycin and kept in incubator (37°C) supplemented with 5% CO 2 and 95% humidity. 4T1 and B16 tumors were minced into small pieces in 37°C Hank's balanced salt solution medium. The tumor pieces were filtered by 70 micro filters to remove Hank's balanced salt solution (HBSS) and then resuspended in tumor digestive enzyme cocktail (Sigma) including collagenase type I (0.05 mg ml -1 ), collagenase type IV (0.05 mg ml-1), hyaluronidase (0.025 mg ml -1 ) and DNase I (0.01 mg ml -1 ) and soybean trypsin inhibitor (0.2 trypsin inhibitor units ml -1 ). The digestion was performed at 37°C until tumor pieces were digested into single-cell suspension. Cell suspension during the digestion process was tested by Trypan blue stain to measure percentage of viable cells. After digestion, cell suspensions were centrifuged to remove enzyme cocktail, washed by Hank's balanced salt solution and then treated by ACK lysis buffer at 37°C for 5-10 min to remove red blood cells. The obtained tumor digest single-cell suspensions were counted and reconstituted in fresh completed DMEM medium at 1 × 10 6 cells ml -1 for further analysis.
Surface staining
The surface expression of CD206, CD74, CD68, CD80, CD11b, dectin-1, CD25 and MHC II by tumor digest cells were determined by surface stain followed by fluorescence-activated cell sorting (FACS) analysis. Cells were centrifuged and resuspended in stain buffer, and then incubated with rabbit isotype immunoglobulin G (IgG) for 20 min. After washing with PBS and resuspending in stain buffer, cells were incubated with PE-conjugated rabbit anti-mouse antibodies for above-mentioned proteins, separately, for 30 min in dark. After staining, cells were washed and fixed by fixative buffer (0.5% paraformaldehyde) for FACS analysis.
Permeabilization and intracellular staining
For intracellular staining of cells, cells were treated using fixation and permeabilization solution kit according to the manufacturer's protocol (BD Biosciences). The permeabilized cells were incubated with rabbit isotype IgG, followed by staining with various fluorescence-conjugated antibodies for 30 min in dark. In this study, we used rabbit anti-mouse AF647-conjugated MIF antibodies, PE-conjugated tumor necrosis factor (TNF)-α, IL-2, IL-6, IL-1β, IL-10, CCL18, IL-12 and TGF-β antibodies for intracellular staining. For intracellular staining of whole blood samples, the blood samples were incubated with pac blue-conjugated anti-mouse CD11b antibody and PE-conjugated anti-mouse GR1 antibody for 30 min, and then treated by ACK red blood cell lysis buffer for 10 min. After centrifugation, the cell pellets were treated by fixation and permeabilization solution kit according to the manufacturer's protocol (BD Biosciences). The permeabilized cells were respectively stained with FITC-conjugated rabbit anti-mouse IL-1β, IL-10 and TGF-β antibodies for 30 min in dark. After intracellular staining, cells were washed and resuspended in stain buffer followed by FACS analysis. For intracellular staining of tumor digest cells, the cells were stained with rabbit isotype IgG followed by AF405conjugated F4/80 antibodies. After surface staining, cells were treated by fixation and permeabilization solution kit according to the manufacturer's protocol. The permeabilized cells were stained with AF647-conjugated MIF antibodies for 30 min in dark. After intracellular staining, cells were washed and resuspended in stain buffer followed by FACS analysis.
Cell proliferation assay
The 4T1 and MDA-MB-231 cells were centrifuged and resuspended in stain buffer followed by permeabilization. The permeabilized cells were incubated with PE-conjugated ki67 antibodies for 30 min in dark. The stained cells were washed by PBS and resuspended in stain buffer followed by FACS analysis within 3 h. Assays were conducted in triplicate.
Apoptosis assay
Apoptosis of cells was determined by FACS analysis using FITC-conjugated Annexin V and 7AAD apoptosis kit according to the manufacturer's protocol. Cells were analyzed via FACS within 3 h. Assays were conducted in triplicate.
FACS analysis
FACS analysis was performed in a BD LSR-II (San Jose, CA, USA) flow cytometer with CellQuest software (Becton Dickinson, Mountain View, USA). Data were processed and analyzed using Winlist software (Verity House Software, Topsham, ME, USA). FACS assays of each sample were conducted in triplicate.
Mouse model
The 7-to 8-week-old female Balb/c mice and C57BL/6J mice were purchased from Jackson Lab (Bar Harbor, ME, USA) and maintained in accordance with the guidelines of the use and care of experimental animals and approved by Animal Research Center of Case Western Reserve University under the protocol number IACUC 2010-0127. In order to obtain 4T1-TAMs and B16-TAMs, we inoculated 4T1 and B16 to the left flank of Balb/c and C57BL/6J, respectively, at 2 million cells per mouse. On day 10 after tumor cell inoculation, mice were killed to collect the subcutaneous 4T1 and B16 tumors. The average tumor size is~6 × 6 mm 2 .
In order to examine the in vivo effect of MIF-siRNA-loaded nanoparticles, we inoculated 4T1-luc tumor cells to the left mammary fat pad of mice and investigated the effect of nanoparticles and controls on the development of tumor, tumor metastasis and tumor-induced immune suppression. Briefly, 1 million tumor cells were injected into the mammary fat pad of mice. Ten days after tumor cell inoculation, nanoparticles containing MIF-siRNA were directly injected into the established 4T1-luc tumor daily for 7 days. The dose of MIF siRNA was 0.8 mg kg -1 day -1 . PBS solution and nanoparticles loaded with scrambled siRNA were used as controls. Mice were then followed for 5 weeks. Experiments were repeated twice using five mice for each group for the first experiment and four mice for each group for the second experiment.
In order to examine the effect of intratumoral administration of MIF-siRNA-loaded nanoparticles on the systemic antitumor effect, we inoculated 4T1 tumor cells on the left mammary fat pad and 4T1-luc tumor on the right mammary fat pad, and then investigated whether the treatment on the left tumor has effect on the growth and metastasis of the siRNA-induced MIF reduction in TME M Zhang et al right tumor. Briefly, 1 × 10 6 4T1 and 4T1-luc cells were injected into the left and right mammary fat pad of mice, respectively. Ten days after 4T1 tumor inoculation, MIF-siRNA-loaded nanoparticles were directly injected into the left 4T1 tumor daily for 7 days. The dose of MIF siRNA was 0.8 mg kg -1 day -1 . PBS solution and nanoparticles with scrambled siRNA were used as controls. Mice were then followed for 4 weeks. Ten mice were used in each group.
Immunohistological fluorescence staining 4T1 tumors from different group of mice were harvested at various time points. Tumor tissues were fixed, embedded, sliced, de-paraffinized and processed according to standard protocol http://www.abcam.com/ ps/pdf/protocols/ihc_p.pdf. Tumor tissues were incubated with rabbit IgG as isotype control followed by the stain with AF405-conjugated F4/80, AF488-conjugated CD206 and AF647-conjugated MIF for 1-2 h in dark. The stained tumor tissue slides were photographed by Carl Zeiss fluorescent microscope LSM 510, and the images were processed by Zeiss LSM Image software (Zeiss, Dublin, Germany). The rabbit IgG were used as isotype control. Assays were conducted in triplicate.
Primary tumor growth curves
Ten days after tumor cells inoculation, sizes of tumors for the treatment and control group of mice were measured daily until mice were killed. Length (L) and width (W) of tumors was measured using caliper. The tumor volume was calculated according to published formula. 17 
Bioluminesence imaging
At various time points, the 4T1-luc-bearing mice from treatment and control groups (nine mice per group) were intraperitoneally injected with 100 μl of D-luciferin (10 mg ml -1 in PBS). After 10 min, mice were imaged under anesthesia with 2.5% isofluorane in a Xenogen IVIS 200 biophotonic Imager (Alameda, CA, USA). Luminescence was expressed as photons s -1 per region of interest minus background luminescence for a similarly sized region.
Pulmonary metastases
At experimental end point, mice from treatment and control groups (nine mice per group) were killed by CO 2 . The rib cage was cut open to expose the lungs and an incision was made on the neck to expose the trachea carefully. Two milliliters of India ink solution (85% India ink in distilled water) was slowly infused into the lungs through the trachea by a 25-gauge needle. The stained lungs were placed in Fekete's solution (90% acetic acid and 37% formaldehyde in 70% ethanol) for de-staining. White tumor nodules against a dark lung background were counted.
Mouse peripheral blood sampling
At various time points, peripheral blood samples were harvested from live mice of different groups (nine mice per group) through saphenous vein puncture. 18 Briefly, the saphenous vein in the leg of mouse was punctured with a 27-gauge needle and the blood was harvested in a sampling tube. Up to 200 μl of blood can be harvested from each mouse twice a week.
Statistical analysis
The data are expressed as the mean values ± s.e. Comparisons between two groups were done using Student's t-test Comparisons among multiple groups were carried out using analysis of variance test. A value of P o0.05 is considered to be statistically significant. Power analysis determined 8-10 mice per group is needed to establish a significant correlation (R40.8).
RESULTS

SiRNA-mediated MIF reduction in 4T1 (murine mammary cancer cell line) and MDA-MB-231 (human breast cancer cell line) resulted in reduced cell proliferation and enhanced cell apoptosis
In order to investigate the in vitro effect of the MIF-siRNA-loaded nanoparticles on MIF expression within cancer cells, we treated murine (4T1) and human (MDA-MB-231) breast cancer cells with MIF-siRNA-loaded nanoparticles for 72 h and then measured intracellular MIF level by FACS. Cancer cells treated with PBS-and scrambled-siRNA-loaded nanoparticle served as controls. FACS histograms were shown in Supplementary Figure 1A and the results were summarized in Figure 1a . Over 90% of both 4T1 and MDA-MB-231 showed high-level MIF expression after the treatment with PBS-and scrambled-siRNA-loaded nanoparticles. After MIF-siRNA-loaded nanoparticle treatment, only 29.4% 4T1 cells and 31.2% MDA-MB-231 cells showed MIF expression and the expression level was significantly reduced. Results of Figure 1a showed that the MIF-siRNA-loaded nanoparticle could result in a significant reduction of intracellular MIF in vitro.
In order to investigate the in vitro effect of the MIF-siRNAloaded nanoparticles on MIF level in extracellular space, we treated murine (4T1) and human (MDA-MB-231) breast cancer cells with MIF-siRNA-loaded nanoparticles for 72 h and then measured extracellular MIF concentrations in cell-conditioned medium by ELISA. Cancer cells treated with PBS-and scrambled-siRNA-loaded nanoparticle served as controls. ELISA results were summarized in Figure 1b . MIF concentrations were high in conditioned medium of both PBS-and scrambled-siRNA-loaded nanoparticle-treated 4T1 (2050 and 2190 pg ml -1 ) and MDA-MB-231 (2250 and 2380 pg ml -1 ) cells. By contrast, MIF concentration in conditioned medium was significantly reduced in the MIF-siRNA-loaded nanoparticle-treated 4T1 (499 pg ml -1 ) and MDA-MB-231 (410 pg ml -1 ) cells. This demonstrated that the MIF-siRNA-loaded nanoparticle could result in a significant reduction of extracellular MIF in cancer cell-conditioned medium in vitro.
Having shown the intracellular and extracellular MIF reduction in 4T1 and MDA-MB-231 cells, we determined the effect of in vitro MIF reduction on cancer cell proliferation ( Figure 1c ) and apoptosis (Figure 1d ), respectively. Cancer cell proliferation was examined by determining the expression level of cell proliferation marker ki67. FACS histogram of ki67 expression by 4T1 and MDA-MB-231 were shown in Supplementary Figure 1B and the results were summarized in Figure 1c . For the PBS-and scrambled-siRNA-loaded nanoparticle-treated cancer cells,~40% 4T1 and 20% MDA-MB-231 cells showed high level of ki67 expression. By contrast, for the MIF-siRNA-loaded nanoparticle-treated cancer cells, only~13.2% 4T1 and~7.8% MDA-MB-231 cells showed ki67 expression. Results of Figure 1c showed that the in vitro siRNAmediated MIF reduction could result in a significant reduction of cancer cell proliferation. Cancer cell apoptosis was examined by determining the percentage of double-positive Annexin V + 7AAD + cell events by FACS. FACS histograms were shown in Supplementary Figure 1C and the results were summarized in Figure 1d . For the PBS-and scrambled-siRNA-loaded nanoparticletreated cancer cells,~20-25% 4T1 and MDA-MB-231 cells (Annexin V + 7AAD + cell events) underwent apoptosis. By contrast, for the MIF-siRNA-loaded nanoparticle-treated cancer cells, 67.3% 4T1 and~55.1% MDA-MB-231 underwent apoptosis. Results of Figure 1d showed that the in vitro siRNA-mediated MIF reduction could result in enhanced apoptosis.
In summary, results of Figure 1 showed that the MIF-siRNAloaded nanoparticles could effectively reduce both intracellular and extracellular MIF in cancer cells in vitro, which associated with significant reduction of cancer cell proliferation and increase of cancer cell apoptosis.
SiRNA-mediated MIF reduction in TAMs resulted in a significant reduction of surface receptor CD206, CD74 and a significant enhanced expression of surface receptor MHC II and intracellular cytokine TNF-α and IL-2 It has been shown in studies that TAMs overexpress MIF. 7, 9, [12] [13] [14] However, the regulatory role of MIF for TAMs is not understood. In order to investigate the in vitro effect of the siRNA-loaded nanoparticles on MIF expression in TAMs, we treated 4T1 and B16 tumor digest cell suspensions with MIF-siRNA-loaded nanoparticles for 72 h and then measured the intracellular and extracellular MIF level of F4/80 + -defined TAMs by FACS ( Figure 2a ) and ELISA (Figure 2b ), respectively.
FACS histograms of intracellular MIF expression by F4/80 + 4T1-TAMs and B16-TAMs were shown in Supplementary Figure 2A and the results were summarized in Figure 2a . For PBS-and the scrambled-siRNA-loaded nanoparticle-treated cells, over 85% of both 4T1-TAMs and B16-TAMs showed high level of intracellular MIF. By contrast, for the MIF-siRNA-loaded nanoparticle-treated cells, only 55.2% 4T1-TAMs and 51.1% B16-TAMs showed positive MIF expression. Therefore, results of Figure 2a showed that the in vitro treatment using the MIF-siRNA-loaded nanoparticle could result in a significant reduction of intracellular MIF in F4/80 + cells (that is, TAMs) within 4T1 and B16 digest cells.
ELISA assay of extracellular MIF level in 4T1 and B16 tumor digest-conditioned medium were summarized in Figure 2b . Ideally, we would use TAM-conditioned medium. However, isolation of TAMs from both 4T1 and B16 tumor digest cells using antibody-conjugated bead column caused damage and led to poor survival of TAMs. As a result of this limitation, we had chosen to detect the overall MIF concentration in tumor digest cell-conditioned medium. Results of Figure 2b showed that the in vitro treatment using MIF-siRNA-loaded nanoparticles resulted in a significant reduction of extracellular MIF in both 4T1 and B16 digest cell-conditioned medium.
Having shown the siRNA-mediated intracellular MIF reduction in TAMs, we determined the effect of in vitro MIF reduction on surface expression of CD206, CD74, CD68, CD80, CD11b, dectin-1, CD25 and MHC II by (F4/80) + 4T1-TAMs and B16-TAMs, respectively. FACS histograms were shown in Supplementary Figure 2B and results were summarized in Figure 2c . As compared with PBS-and the scrambled-siRNA-loaded nanoparticle-treated cells, the MIF-siRNA-loaded nanoparticle-treated cells resulted in a significant reduction of CD206 and CD74, and a significant increase of MHC II in both 4T1-TAMs and B16-TAMs.
Having shown the siRNA-mediated intracellular MIF reduction in TAMs, we also determined the effect of in vitro MIF reduction on intracellular expression of TNF-α, IL-2, IL-6, IL-1β, IL-10, CCL18, IL-12 and TGF-β. FACS histograms were shown in Supplementary Figure 2C and the results were summarized in Figure 2d . As compared with PBS-and scrambled-siRNA-loaded nanoparticletreated cells, the MIF-siRNA-loaded nanoparticle-treated cells showed a significant increase of TNF-α and IL-2 in 4T1-TAMs and B16-TAM.
Intratumoral injection of the MIF-siRNA-loaded nanoparticles resulted in significant reduction of MIF in 4T1 mammary tumor tissue Having demonstrated the siRNA-mediated MIF reduction in both cancer cells and TAMs in vitro, we further determined the siRNA-mediated MIF reduction in vivo in established 4T1 tumors by directly injecting siRNA-loaded nanoparticles to 4T1 tumors in Balb/c mice. Timeline of treatment was shown in Figure 3a . Three days after a 7-day consecutive intratumoral injection of PBS, the scrambled-siRNA-loaded nanoparticles and the MIF-siRAN-loaded nanoparticles into 4T1 tumor (indicated by black arrow), respectively, mice were killed and tumors were harvested. Tumor tissue slices were stained by AF405-conjugated F4/80, AF488-conjugated CD206 and AF647-conjugated MIF (Figure 3b ). Images of Figure 3b -IV demonstrated a high intratumoral MIF level in both PBS-and the scrambled-siRNA-loaded nanoparticletreated tumor tissues. By contrast, the intratumoral MIF level in the MIF-siRNA-loaded nanoparticle-treated tumor tissue was significantly reduced. The MIF levels in the (F4/80-AF405-blue) + (CD206-AF488-green) + TAM-accumulated tumor microenvironment were high in PBS-and the scrambled-siRNA-loaded nanoparticle-treated tumor tissue, but not detectable in the MIF-siRNA-loaded nanoparticle-treated tumor tissue ( Figure 3b -I, II and III). Results of Figure 3b , the immunohistological stain of tumor tissues, showed that the MIF-siRNA-loaded nanoparticles could result in a significant reduction of intratumoral MIF in established tumor tissues including the TAM-accumulated regions.
We also conducted FACS analysis to determine the intracellular MIF expression by 4T1 tumor digest cells obtained after the in vivo administration of nanoparticles (Figure 3c ). This was to determine the effect of in vivo intratumoral MIF reduction on intracellular MIF expression by tumor digest cells. Unstained tumor digest cells served as negative control to gate and determine AF647-MIF + cells. For tumor digest cells obtained from the PBS-and scrambled-siRNA-loaded nanoparticle-treated mice, over 95% cells expressed high level of MIF. For tumor digest cells obtained from the MIF-siRNA-loaded nanoparticle-treated mice, only~14% cells expressed MIF and the expression level was very low. Results of Figure 3c showed that the intratumoral injection of MIF-siRNA-loaded nanoparticles could result in a significant reduction of intracellular MIF in 4T1 tumor digest cells. siRNA-induced MIF reduction in TME Further, for tumor digest cells obtained after the in vivo administration of nanoparticles, we conducted surface stain of cells using AF405-conjugated F4/80 antibody followed by permeabilization and intracellular stain with AF647-conjugated MIF antibody (Figure 3d ). This was to determine the effect of the in vivo intratumoral MIF reduction on intracellular MIF expression by F4/80 + TAMs. Unstained cells served as negative control to gate and determine positive events. For tumor digest cells obtained from the in vivo PBS-and scrambled-siRNA-loaded nanoparticle-treated mice,~61.4% and~58.2% cells showed positive F4/80 expression, respectively, and the expression level was high. Tumor digest cells obtained from the MIF-siRNA-loaded nanoparticle-treated mice showed similar percentage of positive F4/80 expression and the expression level was similarly high, indicating that the nanoparticle treatment did not result in an alteration of total number of TAMs within tumor tissues. The F4/80 + TAMs were further gated to determine intracellular level of MIF. For TAMs obtained from the in vivo PBS-and scrambled-siRNA-loaded nanoparticle-treated mice,~45% and~49% cells, respectively, expressed a high intracellular level of MIF. By contrast, for tumor digest cells obtained from the in vivo MIF-siRNA-loaded nanoparticle-treated mice, only~11% cells expressed low level of MIF. Results of Figure 3d showed that the in vivo intratumoral injection of MIF-siRNA-loaded nanoparticles could result in a significant reduction of intracellular MIF in TAMs.
Intratumoral reduction of MIF resulted in a marked reduction of 4T1 tumor growth and metastasis
In order to determine the effect of the in vivo intratumoral MIF reduction on local tumor development, we measured the 4T1 tumor growth. Ten days after 4T1-luc cell inoculation, sizes of tumors were measured daily (Figure 4a ) to record the tumor growth curves (Figure 4b ). As compared with control groups (PBS-and scrambled-siRNA-loaded nanoparticle-treated groups), the MIF-siRNA-loaded nanoparticle-treated group demonstrated a significant reduction of primary tumor growth. Figure 2 . Small interfering RNA (siRNA)-mediated migration inhibitory factor (MIF) reduction in intracellular space (a) and extracellular space (b) of 4T1-and B16 tumor digest cells resulted in a significant reduction of surface expression CD206 and CD74 (c), a significant increase of surface expression major histocompatibility complex (MHC) II (c), and a significant increase of intracellular cytokines tumor necrosis factor (TNF)-α and interleukin-2 (IL-2) (d) in F4/80 + cells (tumor-associated macrophages (TAMs)). The day-10 4T1 and B16 tumors were harvested from Balb/c and CL57 mice, respectively, and processed into single-cell suspension. The 4T1 and B16 digest cells were treated with phosphate-buffered saline (PBS), the scrambled-siRNA-loaded nanoparticles and the MIF-siRNA-loaded nanoparticles for 72 h, respectively. PBS-and the scrambled-siRNA-loaded nanoparticles served as control. Results of fluorescence-activated cell sorting (FACS) analysis of intracellular MIF expression, the CD206, CD74, CD68, CD80, CD11b, dectin-1, CD25 and MHC II surface expression, and the TNF-α, IL-2, IL-6, IL-1β, IL-10, CCL18, IL-12 and transforming growth factor (TGF)-β intracellular expression, by F4/80 + cells within tumor digest cells were summarized in a, c and d, respectively. Results of enzyme-linked immunosorbent assay (ELISA) assay of MIF concentrations in tumor digest cell-conditioned medium were shown in b. FACS analysis of positive marker events of TAMs within tumor digest cells from three different groups were shown in Supplementary In order to determine the effect of the in vivo intratumoral MIF reduction on tumor metastasis, we measured 4T1-luc tumor metastasis by non-invasive bioluminescence imaging. On days 19, 26 and 33 after 4T1-luc cell inoculation, the mice were non-invasively imaged by bioluminescence imaging to measure tumor metastasis ( Figure 4c ). As compared with control groups (PBS-and the scrambled-siRNA-loaded nanoparticle-treated groups), the MIF-siRNA-loaded nanoparticle-treated groups demonstrated a significant reduction of visible 4T1-luc metastases.
Furthermore, we measured lung metastasis of mice at the preclinical end point by India ink stain method 19 (Figure 4d ). Lungs from three representative mice from each group demonstrated that both PBS-and the scrambled-siRNA-loaded nanoparticle-treated mice had extensive lung metastases (over 15 tumor spots in average), whereas the MIF-siRNA-loaded nanoparticle-treated mice had no or a few metastases (o 3 tumor spots in average).
Therefore, results of Figure 4 showed that the in vivo siRNA-mediated MIF reduction in 4T1 tumors could result in significant reduction of tumor growth and metastasis.
Intratumoral reduction of MIF resulted in a significant reduction of circulating myeloid-derived suppressive cells (MDSC) and the MDSC-expressing suppressive cytokines As it has been shown that 4T1 model associated with significant accumulation of TAMs in tumor microenvironment and significant accumulation of MDSCs in peripheral blood, which correlated with rapid tumor development and metastasis, in this study we determined the effect of in vivo intratumoral MIF reduction on MDSC level in peripheral blood. On day 19 after 4T1-luc cell inoculation, peripheral blood samples were collected from mice and analyzed by FACS ( Figure 5 ). The whole blood samples were stained with Pacific blue-conjugated GR1 (GR1-Pac blue) and PE-conjugated CD11b (CD11b-PE), followed by intracellular stain with FITC-conjugated IL-1β (IL-1β-FITC) or IL-10 (IL-10-FITC) or TGF-β (TGF-β-FITC). In tumor-free Balb/c mice, the baseline percentage of circulating MDSC (CD11b + GR1 + double-positive cells) in blood samples was~8% (Figure 5a-I) . In 4T1 tumor-bearing mice treated by PBS control and the scrambled-siRNA-loaded nanoparticles, cell percentage of the circulating MDSC in blood samples was 83.4% (Figure 5a -II) and 87.1% siRNA-induced MIF reduction in TME (Figure 5a-III) , respectively, indicating that the engrafting of 4T1-luc tumor could induce a significant accumulation of MDSCs in peripheral blood. By contrast, in 4T1-bearing mice treated by the MIF-siRNA-loaded nanoparticles, cell percentage of the circulating MDSC in blood samples was 52.3% (Figure 5a-IV) , indicating that the in vivo intratumoral MIF reduction resulted in a significant reduction of circulating MDSC. Moreover, our FACS results also showed that the circulating MDSCs from mice treated by the MIF-siRNA-loaded nanoparticle demonstrated a significant lower expression of immunosuppressive cytokines including IL-10 and TGF-β than that from mice treated by PBS-and the scrambled-siRNA-loaded nanoparticle (Figure 5b) .
Therefore, results of Figure 5 showed that the in vivo intratumoral reduction of MIF could result in a significant reduction of circulating MDSCs and MDSC-expressing suppressive cytokines.
Intratumoral reduction of MIF within 4T1 tumor resulted in an increased infiltration of T cell with improved antitumoral activity As studies have shown that the in vivo reduction of immune suppression may help to create an environment that is favorable for the development of cell-mediated antitumor immune responses, 20, 21 we determined the effect of the in vivo intratumoral MIF reduction on cell-mediated responses in local tumor. On day 19 after 4T1 cell inoculation, tumors were harvested and digested into single-cell suspensions. The cells were stained with FITC-conjugated CD4 (CD4-FITC) and PE-conjugated CD8 (CD8-PE) antibodies, followed by FACS analysis (Figure 6a) . The treatment and control groups showed similar percentage of CD8 tumor-infiltrated T cells (TILs), whereas the MIF-siRNA-loaded nanoparticle-treated groups showed a marked increase of CD4 TILs, indicating that the in vivo intratumoral MIF reduction resulted in a significant increase of CD4 T-cell infiltration (Figure 6a) .
Further, T cells in the day-19 4T1-GFP tumor digest cell suspension of both treatment and controls groups were isolated by CD3 antibody-conjugated magnetic beads column. The isolated T cells from the treatment and control groups included both CD4 + and CD8 + TILs and were incubated with 4T1-GFP tumor cells in vitro at 2:1 effector to target ratio for 48 h. The co-cultured cells were stained by PE-conjugated CD3 (CD3-PE), Annexin V-AF405 and 7AAD followed byFACS analysis (Figure 6b ). As compared with 4T1-GFP cells in response to the CD4 + and CD8 + TILs isolated from PBS-and the scrambled-siRNA-loaded nanoparticle-treated tumors, the 4T1-GFP cells in response to the CD4 + and CD8 + TILs isolated from the MIF-siRNAloaded nanoparticle-treated tumors underwent a significant reduction of percentage and a significant increase of apoptosis. Figure 6 showed that the in vivo intratumoral MIF reduction in 4T1 tumors could result in a significant increase of TILs both in numbers and in antitumoral function.
Intratumoral reduction of MIF in 4T1 tumor resulted in a reduction of metastasis of a contralateral inoculated 4T1-luc tumor challenge Having shown that the in vivo intratumoral MIF reduction could significantly reduce circulating immunosuppressive factors and enhance TIL infiltration and T-cell-mediated antitumor activity, we examined whether the intratumoral MIF reduction could cause any systemic antitumor effect. In order to test this, we inoculated 4T1 tumor cell on the left flank of mice and the 4T1-luc tumor cells on the contralateral right flank of mice, and then directly injected nanoparticles into the left-flank tumor only. Growth curves of the nanoparticle-treated left-flank 4T1 tumor and the untreated right-flank 4T1-luc tumors are shown in Figure 7a . Compared with PBS-and the scrambled-siRNA-loaded nanoparticle-treated siRNA-induced MIF reduction in TME mice, the MIF-siRNA-loaded nanoparticle-treated mice exhibited minor reduction of tumor growth in both treated (left) 4T1 tumor and untreated (right) 4T1-Luc tumors. However, the difference was not statistically significant.
The untreated right-flank 4T1-luc tumors were imaged by bioluminescence imaging to determine the 4T1-luc metastasis (Figure 7b ). Compared with PBS-and the scrambled-siRNA-loaded nanoparticle-treated mice, the MIF-siRNA-loaded nanoparticletreated mice exhibited delayed development of 4T1-luc metastasis. The metastasis inhibition of the right-flank untreated tumor suggested that a systemic immune response may be generated upon MIF reduction in the left-flank treated tumor.
DISCUSSION
Factors that regulate tumor-TAM interaction are increasingly being viewed as potential therapeutic target for cancers. 6 Increasing evidence has shown that MIF is a major gene product upregulated in tumor microenvironment upon the infiltration and accumulation of TAMs. 7, 8 However, the regulatory role of MIF in Figure 6 . Intratumoral reduction of migration inhibitory factor (MIF) resulted in a significant increase of tumor-infiltrating T cells (TILs) qboth in number (a) and in tumor-reactive responses (b). (a) Fluorescence-activated cell sorting (FACS) analysis of CD4-fluorescein isothiocyanate (FITC) and CD8-phycoerythrin (PE)-positive cells in 4T1 tumor digest cells obtained from mice treated by phosphatebuffered saline (PBS), the scrambled-small interfering RNA (siRNA)-loaded nanoparticle and the MIF-siRNA-loaded nanoparticle. Cells from different groups were incubated with IgG control, followed by surface stain with PE-conjugated CD8 antibody and FITC-conjugated CD4 antibody for FACS analysis. The MIF-siRNA-loaded nanoparticle treatment resulted in a significant percentage increase of CD4 + TILs. (b) FACS analysis of the Annexin V + 7AAD + -defined apoptotic 4T1-GFP tumor cell events after they were incubated with TILs from different groups. The tumor digest cells from different groups were ran through CD3-antibody-conjugated magnetic beads column to isolated CD3 + TILs. The TILs were co-cultured with 4T1-GFP tumor cells at 2:1 ratio for 48 h. After that, cells were incubated with IgG control, followed by surface stain with PE-conjugated CD3 antibody, AF405-conjugated Annexin V and 7AAD for FACS analysis. The MIF-siRNA-loaded nanoparticle treatment resulted in a significant percentage increase of apoptotic tumor cell events. The unstained samples served as control to gate positive cells. PBS-and the scrambled-siRNA-loaded nanoparticle served as controls for MIF-siRNA treatment. 7AAD, 7-Aminoactinomycin D.
siRNA-induced MIF reduction in TME M Zhang et al tumor microenvironment has not been investigated and well understood.
Previously, we have developed a glucan-based cationic nanoparticle system that demonstrated effectiveness of reducing MIF mRNA in both cancer cells and macrophages. 16 Using the nanoparticle system with MIF-siRNA, in this study we were able to reduce MIF expression both in vitro ( Figure 1 ) and in vivo ( Figure 2) .
The in vitro reduction of MIF in tumor cells resulted in a significant reduction of tumor cell proliferation and increase of tumor cell apoptosis, which was observed for both murine 4T1 and human breast cancers MDA-MB-231 ( Figure 1 ). Such observation is consistent with literature findings. 17, 18 MIF has been shown to interact with Jab1 within cells, and the MIF-Jab1 interaction can lead to activation of AKT signaling pathway that promotes cell proliferation and survival. 17 MIF has also been shown to interact with p53, and the MIF-p53 interaction can lead to p53 activation that acts as a transcriptional factor for apoptosis gene. 18 Therefore, our finding that the MIF reduction in breast cancer cells can inhibit cell survival by reducing cell proliferation and increasing cell apoptosis is consistent with the previous finding that MIF in cancer cells can facilitate survival. 17, 18 The in vitro reduction of MIF in TAMs resulted in a significant reduction of factors that marks M2 polarization and significant increase of factors that marks immunogenic capability, which was observed for both 4T1-TAMs and B16-TAMs (Figure 2) . Such observation has not been reported elsewhere. For examples, among the eight surface receptors (CD206, CD74, CD68, CD80, CD1b, dectin-1, CD25 and MHC II) and eight intracellular cytokines (TNF-α, IL-2, IL-6, IL-1β, IL-10, CCL18, IL-12 and TGF-β) detected in this study, we found that the surface expression of CD74 and CD206 were significantly decreased, whereas the surface expression of MHC II as well as the intracellular expression of TNF-α and IL-2 were significantly increased, in both 4T1-TAMs and B16-TAMs (Figure 2c and d) . CD74 has been identified to be MIF receptor. 22 The intracellular domain of CD74 has been associated with the formation of CD74/HLA-DR complexes, which have an important role in antigen presentation. 23, 24 As the CD74/HLA-DR complexes need to constantly internalize to facilitate antigen presentation, the surface level of CD74 by macrophages with good antigen presentation capability (M1 macrophages) is low or negative, whereas the surface level of CD74 by macrophages with poor phagocytosis and/or antigen presentation capability (M2 macrophages) is high. 25, 26 Therefore, the high surface level of CD74 by TAMs indicated a M2 activated macrophages with poor phagocytosis. CD206 is a known M2 activation marker for murine cells. Its high level is associated with reduced macrophage capability of phagocytosis. 27 Surface MHC II has significant role in antigen presentation and its high level is found on M1 activated macrophages. TNF-α by macrophages has been shown to have important role in connecting innate and adaptive immunity. 28, 29 In addition, IL-2 is a well-known growth factor for T cells. 30 Based on these, the significant reduction of CD74 and CD206, and significant increase of MHC II, IL-2 and TNF-α in nanoparticle-treated TAMs strongly suggested a reduction of M2 polarization and an increase of immunogenic capability of TAMs. In order to bring down MIF level in vivo in tumor microenvironment, we conducted a direct injection of high-dose MIF-siRNAloaded nanoparticles into established 4T1 tumors in mice daily for 7 days, which effectively reduced the overall MIF level in tumor tissues including the regions with significant TAMs accumulation (Figure 3 ). This resulted in a significant reduction of 4T1 tumor growth and metastasis (Figure 4 ), significant reduction of circulating MDSCs both in number and in suppressive function ( Figure 5) , and significant increase of T cells both in number and in tumor-reactive responses ( Figure 6 ). Noted that the T cells (TILs) investigated in Figure 6 were isolated by CD3 + antibodyconjugated beads so that the TILs included both CD4 + and CD8 + T cells. These TILs showed a direct killing of cancer cells in co-culture, however, our results did not specify whether the CD4 + or CD8 + T cells mediated the direct killing.
Delayed tumor growth and metastasis have been previously reported in a MIF total knockout B16 murine melanoma model, suggesting the role of MIF in tumor development. 31 However, no study has ever correlated intratumoral MIF with MDSC in cancer models. Recent studies in animal models and breast cancer patients have demonstrated that MDSC is one of the central regulators of tumor-induced immune suppression. 32 Tumor has been found to use mechanism to block the immature myeloid cells from differentiating into mature granulocytes, macrophages and dendritic cells, which results in the generation of immunosuppressive MDSCs, which progressively accumulate in peripheral blood, lymphatic organ and tumor to facilitate immune escape and inhibit the development of antitumoral immune responses. 33, 34 Noted that it has been shown by some cases that the reduction of circulating MDSCs can be caused by a reduced tumor burden. 34 In our study, the intratumoral MIF reduction resulted in MDSCs reduction both in number (Figure 5a ) and in suppressive functions (Figure 5b ), providing evidence that the MDSC reduction is caused by the intratumoral modulation of MIF. In addition, no study has ever correlated intratumoral MIF with T-cell-mediated immune responses within tumors. Therefore, our observation that the intratumoral MIF reduction could significantly reduce tumor growth/metastasis, reduce MDSCs and increase functionality of TILs strongly suggested a regulatory role of MIF in modulating immune responses through reducing immune suppression.
Further, the development of systemic antitumor responses upon intratumoral MIF reduction was observed by using a mice model engrafted with 4T1 tumor on the left flank and 4T1-Luc tumor on the right flank ( Figure 7) . The MIF-siRNA-loaded nanoparticles were only injected to the left 4T1 tumors. Therefore, if the local intratumoral MIF therapy on left-flank 4T1 tumor could cause any systemic antitumor responses, the untreated right-flank 4T1-luc tumor progressions should be affected. As our results showed that the untreated right-flank 4T1-luc tumors exhibited reduced metastasis (Figure 7b ), it strongly suggested that the local intratumoral MIF therapy using nanoparticle system with MIF-siRNA could result in a development of systemic antitumor responses. Noted that the dose of the MIF-siRNA-loaded nanoparticles used for the left-flank 4T1 tumor (Figure 7a , left) was the same as that used for 4T1 tumors in Figure 4b . However, the MIF-siRNA-loaded nanoparticle-mediated reduction of tumor growth in Figure 4b was more significant than that in Figure 7a . This may be because that mice in Figure 7a carried tumors on both flanks, whereas the mice in Figure 4b carried tumor on only one flank. The bigger tumor burden may have reduced the efficacy of the MIF-siRNA-loaded nanoparticles in vivo.
This study demonstrated for the first time that the MIF reduction in TAM-accumulated tumor microenvironment not only inhibited tumor development, but also provoked systemic antitumor immune responses. Based upon the results, we believe that the intratumoral MIF represent an innovative immunotherapeutic target for breast cancer because of its correlation with MDSC and T cells in vivo.
MIF local therapy anticipates to having significant clinical application for patients with injectable tumors such as breast tumors. Increasing studies have shown that MIF is overexpressed by invasive and non-invasive breast cancers and characterize estrogen-sensitive and -insensitive breast cancers alike; 14 MIF overexpression has been shown to associate with reduced or diminished expression of estrogen receptors and progesterone receptors of breast cancers. 14 Thus, therapy-targeting intratumoral MIF can be used to release patients from immunosuppressive state and then combined with other subtherapeutic options to treat various types and stages of breast cancers.
